Dataset from A Phase III Multicentre, Double Blind, Placebo-controlled, Parallel Group 52-week Study to Assess the Efficacy and Safety of 2 Dose Regimens of Lyophilised CDP870 as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate

Patients will be assigned to one of three treatment groups. Study medication is administered over a 52 week study duration.

受试者将被分配至三个治疗组中的一组。研究药物的给药将贯穿整个52周的研究周期。